Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piper guineense extract is a botanical preparation derived from the West African pepper plant, commonly known as Uziza or Guinea pepper. It contains a complex mixture of bioactive compounds, including piperine and piperamide alkaloids, flavonoids, and tannins. The extract is primarily researched for its anti-sickling properties in the treatment of sickle cell disease, notably as a component of the phytomedicine NIPRISAN (also known as NICOSAN), developed by the National Institute for Pharmaceutical Research and Development (NIPRD) in Nigeria. Additionally, it exhibits inhibitory effects on alpha-amylase and alpha-glucosidase enzymes, suggesting potential utility in managing postprandial hyperglycemia and type 2 diabetes. Other investigated pharmacological activities include antimicrobial, antioxidant, and analgesic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piper guineense extract.